Nexalin Technology, Inc. (NXL) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Nexalin Technology, Inc. is a medical device company developing neurostimulation products to treat mental health conditions (anxiety, insomnia, depression) and neurodegenerative diseases (Alzheimer's, dementia). The company operates as a single segment and is currently classified as a Smaller Reporting Company and Emerging Growth Company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Net Revenue | $12,161 | $27,111 |
| Gross Profit | $8,897 | $22,030 |
| Gross Margin | 73.2% | 81.3% |
| Net Loss | $(2,239,170) | $(4,336,007) |
| Net Loss Per Share (Basic & Diluted) | $(0.11) | $(0.21) |
| Cash and Cash Equivalents | $1,004,958 (as of June 30, 2026) | |
| Working Capital | $377,350 (as of June 30, 2026) | |
| Accumulated Deficit | $(97,203,419) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 83% quarter-over-quarter (QoQ) and 76% year-over-year (YoY) for the six-month period. The decline is attributed to the cessation of international equipment sales and a shift toward lower-volume licensing revenue.
- Increased Operating Expenses: Total operating expenses rose 35% QoQ and 18% YoY (six months). This was driven primarily by a 150% QoQ increase in Research and Development (R&D) expenses due to the initiation of the FDA-cleared insomnia clinical trial for the Gen-3 HALO device.
- Acquisition Activity: In May 2026, the company acquired PONM, Inc. for approximately $1.3 million in stock consideration to enhance its Nexalin NeuroCare digital health platform. This resulted in a new deferred share liability of approximately $387,000.
- Cash Flow: Net cash used in operating activities increased to $3.5 million for the six months ended June 30, 2026, compared to $2.3 million in the prior year period, reflecting higher operational burn rates.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the filing date. The company does not have sufficient cash to fund anticipated operations and requires additional capital.
- Nasdaq Delisting Risk: The company received a Staff Delisting Determination from Nasdaq on July 24, 2026, for failing to maintain the $1.00 minimum bid price. A hearing has been requested to stay delisting. The Board has approved a 30-for-1 reverse stock split to regain compliance, but it has not yet been effected.
- Capital Raising: The company relies on its At-The-Market (ATM) offering program for liquidity. Delisting would impair the ability to use the ATM program, severely impacting liquidity. Approximately $2.65 million remains available under the ATM program.
- Clinical Progress: The company initiated the pivotal clinical trial for the Gen-3 HALO device for insomnia. The FDA accepted a Q-Submission for the Gen-2 SYNC system targeting Alzheimer's disease in October 2025.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and IT access controls.
Investor Verification Checklist
- Delisting Status: Verify the outcome of the Nasdaq Hearings Panel and the implementation status of the 30-for-1 reverse stock split.
- Liquidity Runway: Assess the timeline and terms of any new equity financing required to fund the ongoing insomnia clinical trial and operations.
- ATM Program Viability: Confirm if the ATM program remains active and effective given the delisting proceedings.
- Acquisition Integration: Monitor the integration of PONM, Inc. assets and the performance of the Nexalin NeuroCare platform.
- Clinical Trial Milestones: Track patient recruitment and data readouts for the Gen-3 HALO insomnia trial.